Clinical trial · Interventional
99mTc-CNDG Injection in the Diagnosis of Malignant Tumors
A Prospective Study to Explore the Performance and Efficacy of 99mTc-CNDG Injection in Malignant Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Currently, 18F-fluorodeoxyglucose (18F-FDG) is the most widely used tumor imaging agent in clinical practice. However, the production of 18F requires accelerators and is associated with relatively high diagnostic costs, which to some extent limits its widespread clinical application. In comparison to Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT) devices are more abundant and offer lower diagnostic expenses. With the utilization of Cadmium Zinc Telluride (CZT) crystals in SPECT and advancements in image reconstruction techniques, the resolution and sensitivity of SPECT is continually improving. Therefore, the development of a simplified and cost-effective novel SPECT tumor imaging agent holds significant practical significance. This study involved the design and synthesis of a glucose-derived ligand with a linker containing seven methylene units and an isonitrile group (CN7DG). The CN7DG ligand was labeled with 99mTc to prepare a more lipophilic 99mTc-CN7DG complex, aiming to investigate a novel SPECT imaging agent for tumor imaging.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Tumor | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 99mTc-CNDG SPECT/CT | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 99mTc-CNDG SPECT/CT
- description
- Inject 99mTc-CNDG and then perform SPECT/CT scan.
- interventionNames
- Diagnostic Test: 99mTc-CNDG SPECT/CT
Primary outcomes (3)
- measure
- Uptake value of 99mTc-CNDG in malignant tumors
- timeFrame
- through study completion, an average of 1 year
- description
- The uptake value was measured in the malignant lesions on 99mTc-CNDG SPECT/CT.
- measure
- Lesions detected by 99mTc-CNDG SPECT/CT
- timeFrame
- through study completion, an average of 1 year
- description
- The number of target lesions was calculated by 99mTc-CNDG SPECT/CT
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * 18-70 years old * Patients diagnosed with malignant glioma, colorectal cancer, pancreatic cancer, lung cancer, breast cancer, or other malignant tumors through imaging techniques such as MRI, CT, and ultrasound, and who are scheduled for surgical resection or biopsy * Solid tumor sizes greater than 2cm * Voluntarily agree to participate and sign an informed consent form * Can provide complete surgical records, pathological results, control data, and clinical follow-up results Exclusion Criteria: * Pre-treatment such as chemotherapy and targeted therapy has been administered * Pregnancy and breastfeeding * Claustrophobia * The condition is severe and difficult to cooperate with * Unable to obtain relevant control imaging data and clinical information
References
Publications (0)
Data not yet available